FEATURED

Drug Manufacturers Delayed Reporting AEs

One in every 10 serious adverse drug events, including deaths, was not reported to the FDA within regulation timelines.

ASCO: More Older Adults in Trials

While most cancer drugs are prescribed to older adults, they are underrepresented in clinical trials.

Molecular Testing in Hematopathology

Molecular testing is entrenched in the workup and management of hematological malignancies.

The Changing Treatment Landscape in PCa

Numerous drug approvals for treatment of prostate cancer over the last decade hold hope for patients, but more research is needed to convert it to a chronic disease.

Drug Showcase: ELITEK (rasburicase)

Indicated for initial management of plasma uric acid levels.

E-cigs Remain Despite Lack of Oversight

Despite reports to the FDA regarding adverse events of e-cigarettes and concerns from health organizations, sales continue without regulatory oversight.

Controversy Remains Regarding TARGIT-A Results

Results from the international, noninferiority phase 3 TARGIT-A trial continue to be questioned by researchers and patient advocacy groups.

New Approvals Shift CLL Treatment

The approvals of obinutuzumab, ibrutinib, and idelalisib provide clinicians with new treatment options for patients with CLL.

Genetic Counseling Could Affect PCa Treatment

A new study highlights the need for genetic counseling, which could help determine treatment options for certain patients.

XTANDI Practice and Patient Resources

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

Concerns Raised Regarding Delays in Mandatory Drug Death Reporting

Concerns Raised Regarding Delays in Mandatory Drug Death Reporting

One in every 10 serious adverse drug events, including deaths, was not reported to the FDA within regulation timelines.

ASCO Statement on Increasing the Number of Older Patients in Clinical Trials

ASCO Statement on Increasing the Number of Older Patients in Clinical Trials

While most cancer drugs are prescribed to older adults, they are underrepresented in clinical trials.

Feature Articles

Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology

Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology

[Cancer Control] Molecular testing is entrenched in the workup and management of hematological malignancies.

A Decade of Dramatic Change in the Treatment of Prostate Cancer

A Decade of Dramatic Change in the Treatment of Prostate Cancer

Numerous drug approvals for treatment of prostate cancer over the last decade hold hope for patients, but more research is needed to convert it to a chronic disease.

Featured Videos

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs